Molecular Partners highlights bispecific Radio-DARPins at Gordon Research Conference
MOLN•Program updates and pipeline timeline
Lead candidate MP0712, targeting DLL3, is in a multicenter U.S. Phase 1/2a trial with Orano Med.
Second candidate MP0726, targeting mesothelin, is expected to reach first human imaging this year.
The company expects to announce a third Radio-DARPin program in 2026.
Bispecific Radio-DARPins highlighted at conference
Molecular Partners highlighted the development of bispecific Radio-DARPins designed to engage multiple tumor targets, aiming to improve precision in radioligand therapy.
It said multispecific formats could address tumor heterogeneity, building on its mono-targeting Radio-DARPin programs.
